Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Refresh Tears Clear all
Completed Phase 3 Interventional Results available

A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

NCT06544694
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, Artificial Tears
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Louisville, Kentucky • Garner, North Carolina • Leland, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Phase 1 Interventional

Study of ST266 Eye Drops in Treating Dry Eye

NCT02369861
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
ST266, Refresh Lubricant Eye Drops
Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.

NCT02553772
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Based Eye Drop, Carboxymethylcellulose Sodium 0.5%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
10
States / cities
Azusa, California • Burbank, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fluorophotometry Evaluation of Lubricant Eye Drops

NCT00347854
View directory record Official record
Conditions
Healthy
Interventions
Systane Free lubricant eye drops, Visine Tears Lubricant Eye Drops, Refresh Liquigel Lubricant Eye Drops, Refresh Plus Lubricant Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 2, 2026, 12:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

NCT07284381
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ABBV-444, REFRESH OPTIVE UD
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Dothan, Alabama • Chandler, Arizona • Azusa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome

NCT05292755
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose (CMC) Artificial Tears, Preservative-free, CMC-free Artificial Tears (control)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows

NCT01891487
View directory record Official record
Conditions
Hypotrichosis
Interventions
Track A, Track B
Drug
Lead sponsor
ATS Clinical Research
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

NCT00514852
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Carboxymethylcellulose and Glycerin based artificial tear, Carboxymethylcellulose
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients

NCT00611403
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®), Artificial Tears REFRESH ENDURA®
Drug
Lead sponsor
Allergan
Industry
Eligibility
21 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Topical Antibiotic Prophylaxis for Eyelids

NCT03199911
View directory record Official record
Conditions
Antibiotic Side Effect, Eyelid; Wound, Eyelid Diseases, Surgical Wound Infection, Surgical Wound, Recent, Surgical Incision, Skin Cancer Face, Antibiotic Allergy, Surgical Site Infection
Interventions
Topical Antibiotic Product, Topical Non-Antibiotic Ointment
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

NCT04393441
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Azusa, California • Glendale, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Not applicable Interventional Results available

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

NCT00932477
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Glycerin and Polysorbate 80 based artificial tear
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Not applicable Interventional Results available

The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction

NCT01207752
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Systane Balance, Optive Lubricant Eye Drops
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 2, 2026, 12:32 PM EDT
Recruiting No phase listed Observational

Long-term Effects of Acoltremon vs. Control in Dry Eye Disease

NCT07659626
View directory record Official record
Conditions
Dry Eye
Interventions
Acoltremon 0.003%, Refresh classic preservative free
Drug
Lead sponsor
The Eye Care Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 2, 2026, 12:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

NCT02975557
View directory record Official record
Conditions
Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
Interventions
Brimonidine 0.15%, Brimonidine 0.075%, Placebo
Drug
Lead sponsor
Sandeep Jain, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 2, 2026, 12:32 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

NCT00634972
View directory record Official record
Conditions
Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions
ACULAR, REFRESH TEARS, placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
10 Days to 15 Days
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 2, 2026, 12:32 PM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects

NCT01010282
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Glycerin and Polysorbate 80 based artificial tear, Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2015 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Artificial Tears, Tear Lipids and Tear Film Dynamics

NCT05705518
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Complete PF, Refresh Relieva PF, Refresh Optive Mega-3 PF, CVS Health Lubricant Eye Drop (PG 0.6%)
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 2, 2026, 12:32 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms

NCT01382810
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Altaire Gel forming solution, Refresh Tears
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Lake Villa, Illinois • Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cool vs Room-temperature Artificial Tears

NCT05832996
View directory record Official record
Conditions
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain
Interventions
Refresh Plus Preservative-free Lubricant Eye Drops
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 105 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing

NCT01128556
View directory record Official record
Conditions
Histamine Responsive Allergy Patients
Interventions
Bepreve, Refresh Tears
Drug
Lead sponsor
North Texas Institute for Clinical Trials
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Sep 2, 2026, 12:32 PM EDT
Completed Phase 4 Interventional

Soothe Versus Refresh

NCT00284999
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Soothe, Refresh Tears
Drug
Lead sponsor
Pharmaceutical Research Network
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
3
States / cities
Atlanta, Georgia • Southfield, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2006 · Synced Sep 2, 2026, 12:32 PM EDT
Terminated Phase 4 Interventional

Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests

NCT04125134
View directory record Official record
Conditions
Dry Eye
Interventions
Preservative-free Refresh Optive Advanced Lubricant Eye Drops
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 2, 2026, 12:32 PM EDT